肌肉痙攣市場：依藥物類型、給藥途徑、通路及地區分類

預計到 2026 年，肌肉痙攣市場規模將達到 114 億美元，到 2033 年將達到 237 億美元。預計從 2026 年到 2033 年，該市場將以 8.9% 的複合年成長率成長。

肌肉痙攣（或肌肉抽搐）是指肌肉僵硬或收縮的一種狀態。它可發生於多種疾病，包括脊髓損傷、腦損傷以及肌萎縮側索硬化症（ALS）和多發性硬化症（MS）等疾病。當控制肌肉運動的神經衝動受損或受阻時，就會發生肌肉痙攣。肌肉痙攣會導致言語、運動和拉伸困難。

肌肉痙攣的症狀多種多樣，包括肌張力增高、不自主運動、姿勢異常、疼痛或不適、骨骼和關節畸形以及功能障礙。當痙攣引起疼痛、干擾日常生活或睡眠，或導致功能障礙時，就需要治療。治療方案根據患者的需求、意願和目標而定。治療方法可能包括物理治療、職業治療、使用石膏或矯正器具以及口服藥物。在某些情況下，可能需要手術。口服藥物僅在症狀干擾日常生活或睡眠時使用。常用藥物包括Baclofen、丹曲林鈉、肉毒桿菌和Diazepam。

市場動態

預計在預測期內，肌肉痙攣治療新藥上市和法規核准數量的增加將推動市場成長。例如，2021年7月，默茲集團旗下神經毒素領域的領先企業默茲治療公司（Merz Therapeutics）與帝人集團的核心醫療保健業務帝人製藥株式會社（Teijin Pharma Limited）聯合宣布，帝人製藥已獲得日本厚生勞動省的額外批准，可銷售用於治療下肢痙攣的神經毒素Xeomin（AXeomin。

本報告的主要特點

• 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
• 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
• 本節根據各種參數（公司概況、產品系列、主要趨勢、財務表現、策略等）介紹全球肌肉痙攣市場的主要公司。
• 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
• 《全球肌肉痙攣市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過分析全球肌肉痙攣市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 機會
• 影響分析
• 主要亮點
• 管道分析
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特五力分析
• 商業合作與企業合併趨勢

第4章：全球肌肉痙攣市場：依藥物類型分類（2021-2033 年）

• Baclofen
• 肉毒桿菌毒素
• Diazepam
• Tizanidine
• 丹曲林鈉
• 其他

第5章 全球肌肉痙攣藥物市場：依給藥途徑分類（2021-2033 年）

• 口服
• 肌肉內注射
• 其他

第6章：全球肌肉痙攣市場：依通路分類（2021-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球肌肉痙攣市場：依地區分類（2021-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第8章 競爭情勢

• 熱圖分析
• 市佔率分析
  • Ipsen Pharma
  • Allergan
  • Acorda Therapeutics, Inc.
  • Merz Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Beximco Pharmaceuticals Ltd.
  • Johnson & Johnson Private Limited
  • Zydus Cadila
  • Hoffmann-La Roche Ltd
  • Elite Pharmaceuticals Inc

第9章

• 分析方法
• 關於 Coherent Market Insights

Muscle Spasticity Market is estimated to be valued at USD 11.4 Bn in 2026 and is expected to reach USD 23.7 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.9% from 2026 to 2033.

When muscles become stiff or contract, the condition is called as muscle spasticity. Muscle spasticity is seen in a variety of conditions such as spinal cord injury, brain injury, diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). It occurs when the nerve impulses involved in controlling muscle movement are either damaged or interrupted. Muscle spasticity can cause a difficulty in talking, moving, or stretching.

Symptoms of muscle spasticity include increased muscle tone, involuntary movements, abnormal posture, pain or discomfort, bone and joint deformities, decreased ability to function, and others. Spasticity should be treated when it causes pain, interferes with daily activities or sleep, or leads to decreased ability to function. Treatment given is based on the patient's needs, preferences, and goals. The treatment includes physical therapy, occupational therapy, casting or bracing, and oral medications. Surgery may also be needed in certain cases. Oral medications are only used when the symptoms interfere with daily activities or sleep. Common medications include baclofen, dantrolene sodium, botulinum toxin, diazepam, and others.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for muscle spasticity are expected to drive the market growth during the forecast period. For instance, in July 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group's healthcare business, jointly announced that Teijin Pharma was granted additional approval by Japan's Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA), a neurotoxin treatment for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.

Key features of the study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global muscle spasticity market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global muscle spasticity market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle spasticity market

Market Segmentation

• By Drug Type (Revenue, USD Bn, 2021-2033)
• Baclofen
• Botulinum Toxin
• Diazepam
• Tizanidine
• Dantrolene Sodium
• Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
• Oral
• Intramuscular
• Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Beximco Pharmaceuticals Ltd.
• Johnson & Johnson Private Limited
• Zydus Cadila
• Hoffmann-La Roche Ltd.
• Elite Pharmaceuticals Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunity
• Impact Analysis
• Key Highlights
• Pipeline Analysis
• Regulatory Scenario
• Product Launches / Approvals
• PEST Analysis
• PORTER's Analysis
• Merger, Collaboration and Acquisitions Scenario

4. Global Muscle Spasticity Market, By Drug Type, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Baclofen
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Botulinum Toxin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Diazepam
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Tizanidine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Dantrolene Sodium
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Muscle Spasticity Market, By Route of Administration, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Intramuscular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Muscle Spasticity Market, By Distribution Channel, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Muscle Spasticity Market, By Region, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2021-2033, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
  • Ipsen Pharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Allergan
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Acorda Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merz Pharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Beximco Pharmaceuticals Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson Private Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Zydus Cadila
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Elite Pharmaceuticals Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Analyst Views

9. Section

• Research Methodology
• About us